Human papillomavirus types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 (HR-HPV)

Human papillomavirus (HPV) types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 are classified as high-risk (oncogenic) genotypes within the Papillomaviridae family (National Cancer Institute, 2023). These viruses primarily infect cutaneous and mucosal epithelium, where they can integrate into the host genome and express the oncoproteins E6 and E7. These proteins facilitate oncogenesis by targeting and degrading host tumor suppressors p53 and pRb, respectively, leading to genomic instability and malignant transformation (PubMed: PMID 29113925). While several of these types (31, 33, 45, 52, 58) are directly targeted by the 9-valent HPV vaccine, others contribute significantly to the global burden of cervical, anal, and oropharyngeal cancers (FDA, 2020). Current therapeutic interventions are primarily prophylactic, utilizing virus-like particles (VLPs) composed of the recombinant L1 major capsid protein to elicit a protective antibody response. Management of infections caused by these types involves rigorous screening via DNA testing and monitoring for precancerous lesions such as cervical intraepithelial neoplasia.

Other names

High-risk Human papillomavirusOncogenic HPVAlphapapillomavirusGroup 1 Carcinogenic HPV types

Induction of a humoral immune response leading to the production of neutralizing antibodies against the L1 major capsid protein, which prevents viral entry into host basal epithelial cells (CDC, 2021).